Compositions capable of promoting mitofusin activation may include a mitofusin activator having a structure represented by

##STR00001##

any stereoisomer thereof, or any pharmaceutically acceptable salt thereof. G is N or CH, and A is an optionally substituted 5- or 6-membered cycloalkyl or heterocycloalkyl ring. X is (CH.sub.2).sub.3,OCH.sub.2CH.sub.2, CH.sub.2OCH.sub.2, CH.sub.2CH.sub.2O, Cyc, CH.sub.2Cyc, NR.sup.1 (CH.sub.2).sub.3,NR.sup.1OCH.sub.2CH.sub.2, NR.sup.1CH.sub.2OCH.sub.2, NR.sup.1CH.sub.2CH.sub.2O, or NR.sup.1Y, R.sup.1 is H or C.sub.1-C.sub.6 alkyl, and Cyc is 1,2-cyclopropyl, 1,2-cyclobutyl, 1,3-cyclobutyl, 1,2-cyclopentyl, 1,3-cyclopentyl, 1,2-cyclohexyl, 1,3-cyclohexyl, or 1,4-cyclohexyl. Z is (CH.sub.2).sub.n or (CH.sub.2).sub.n.sub.1 O(CH.sub.2).sub.n.sub.2. R.sup.2 is an optionally substituted aryl or heteroaryl group. Variable n is an integer ranging from 1 to 5, variable n.sub.1 is an integer ranging from 0 to 4, variable n.sub.2 is an integer ranging from 0 to 4, and n.sub.1+n.sub.2=n1.

Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein RC(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1 and HIF-2 proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

##STR00001##

Triterpenoid derivatives and compositions comprising said triterpenoids derivatives of Formula (I) are described, wherein RC(O)NHOH. Said triterpenoids and compositions show capacity to bind PHD2, stabilize HIF-1 and HIF-2 proteins, activate the HIF pathway in different cell types, induce angiogenesis in human endothelial vascular cell, show neuroprotective activity in vitro and in vivo, antidiabetic activity and reduce the levels of lipids in vivo, and increase the plasma levels of Erythropoietin in vivo. The triterpenoid derivatives described act also in a selective manner and do not induce Nrf2 activation, NF-B inhibition, STAT3 inhibition, and TGR5 activation, which are known activities of the natural triterpenoid precursors. Said triterpenoid derivatives are useful in the treatment of conditions and diseases which are responsive to HIF activation such as stroke, cerebral palsy, traumatic injuries and neurodegenerative diseases; and also IBD, myocardial ischaemia-reperfusion injury, acute lung injury, diabetic and chronic wounds, organ transplantation, acute kidney injury or arterial diseases.

##STR00001##

Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##

Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, or pharmaceutically acceptable salts thereof, compositions thereof, and methods of their use. ##STR00001##

The method of the present invention for converting a nitrile functional group into a hydroxamic acid functional group can be easily performed at room temperature and under normal pressure by using a peroxocobalt complex. The final hydroxamic acid functional group produced through the intermediate Hydroximatocobalt (III) compound or the derivative comprising the same has been known to be able to inhibit the growth of cancer cells, so that the conversion method of the present invention can be applied to the preparation of a pro-drug for anticancer treatment.

The method of the present invention for converting a nitrile functional group into a hydroxamic acid functional group can be easily performed at room temperature and under normal pressure by using a peroxocobalt complex. The final hydroxamic acid functional group produced through the intermediate Hydroximatocobalt (III) compound or the derivative comprising the same has been known to be able to inhibit the growth of cancer cells, so that the conversion method of the present invention can be applied to the preparation of a pro-drug for anticancer treatment.

Disclosed herein are histone deacetylase imaging agents for positron emission tomography and related imaging methods using the histone deacetylase imaging agents. The histone deacetylase imaging agents may be a compound of formula (I):

##STR00001##

wherein R.sup.1 is a moiety including a positron emitter; R.sup.2 represents hydrogen, or substituted or unsubstituted alkyl, or substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and n is an integer selected from 0 or 1. In one version of the compound of formula (I), R.sup.1 is a moiety including an adamantyl group.